Navigation Links
Last Year's H1N1 Flu Vaccine Was Safe, Study Finds
Date:2/3/2011

By Steven Reinberg
HealthDay Reporter

WEDNESDAY, Feb. 2 (HealthDay News) -- Close to 100 million doses of H1N1 flu vaccine were given out in 2009-2010 in China, with no pattern of serious side effects observed, a review by Chinese scientists finds.

Moreover, no evidence surfaced that the swine flu vaccine, as it was called, increased the risk for Guillain-Barre syndrome, according to the report published in the Feb. 2 online edition of the New England Journal of Medicine.

An outbreak of Guillain-Barre around the time of widespread vaccination against swine flu in 1976-1977 led some to blame the vaccine for the disease. In Guillain-Barre, the body's immune system attacks the nervous system causing muscle weakness and paralysis.

Back then, some 1,000 cases of Guillain-Barre syndrome were reported, about half in people vaccinated. Hypothetically, a case could have been made that they were a reaction to the H1N1 antigen in the vaccine, said flu expert Dr. Marc Siegel, an associate professor of medicine at New York University in New York City.

Some concerns surfaced about the safety of the H1N1 vaccine recommended in 2009-2010 against the H1N1 pandemic.

But this study clearly shows that last year's H1N1 vaccine was not associated with increases in Guillain-Barre syndrome, Siegel said.

"If anybody still thinks that pig viruses cause Guillain-Barre at an increased rate, this study shows that's not the case," he said.

Noting that this year's seasonal flu vaccine contains last year's H1N1 vaccine, Siegel said, "there is no reason to be concerned that this antigen is in the current vaccine."

For the study, a team led by Dr. Yu Wang, from the Chinese Center for Disease Control and Prevention's National Immunization Program in Beijing, collected data on any adverse effects from the vaccine from doctors throughout China.

In all, 89.6 million doses of H1N1 vaccine were given from the end of September 2009 through March 2010. A total of 8,067 adverse events was reported. That's a rate of 90 adverse reactions for every million doses, the researchers noted.

However, only 6,552 of the adverse reactions proved to be related to the vaccine -- a rate of 73.1 per million doses, Wang's group said.

Among the most serious were allergic reactions, which accounted for about 13 percent of all the events. Eleven cases of Guillain-Barre syndrome were reported among those vaccinated, a rate of 0.1 per million doses, which is lower than the normal rate of the disease in China, Wang's team found.

"These findings suggest that the H1N1 vaccine has a reasonable safety profile, and there is no evidence that the vaccine is associated with an increased risk of the Guillain-Barre syndrome," the researchers concluded in their report.

Commenting on the study, Dr. Bruce Farber, chief of the Division of Infectious Diseases at North Shore University Hospital in Manhasset, N.Y., said that "as we know from the H1N1 experience in the U.S. last year, our vaccine was safe.

"Despite the initial public skepticism and some cynicism, influenza vaccines are safe and effective," he added. "The risk-benefit ratio, which is what vaccines and everything in medicine is about, is overwhelmingly in favor of vaccination."

Mild side effects were more common among children aged 9 and younger who were vaccinated than for older adults, the study found.

Each year in the United States about 36,000 people die from complications from the flu, and the vaccine is the best protection against getting the flu in the first place, according to the U.S. Centers for Disease Control and Prevention.

More information

For more information on the flu, visit the U.S. Centers for Disease Control and Prevention.

SOURCES: Marc Siegel, M.D., associate professor, medicine, New York University School of Medicine, New York City; Bruce Farber, M.D., chief, Division of Infectious Diseases, North Shore University Hospital, Manhasset, N.Y.; Feb. 2, 2011, New England Journal of Medicine, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. An extra 5 years of life an unexpected benefit of osteoporosis treatment
2. Parents Divorce May Contribute to Suicidal Thoughts Years Later
3. 10 years later: Robotic surgery for prostate cancer
4. Fast Walkers May Have More Years Ahead of Them
5. Prevention of bad lifestyle habits should be tackled even before 13 years
6. Personalized vaccine for lymphoma patients extends disease-free survival by nearly 2 years
7. 30 years on in the epicenter of the African AIDS epidemic
8. Bowel cancer: 8 years of colonoscopy screening in Germany -- a success story
9. Activity Level Seems to Decline Throughout College Years
10. Americans Salt Intake Unchanged Over 50 Years
11. Older women with normal T-scores may not need bone mineral density screening for 10 years
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Last Year's H1N1 Flu Vaccine Was Safe, Study Finds  
(Date:4/28/2017)... New York, NY (PRWEB) , ... April 28, ... ... Shiel Medical Laboratory to expanded distribution of the GlycoMark test throughout the Northeast ... indicates recent hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly ... offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and ... These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back Surgery and ... revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified Anesthesiologist, with ... revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike traditional back ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... The Texas ... in recently to the labor and delivery team at Women’s Hospital at Renaissance in ... who give birth at the hospital and decide to donate. , “Women’s Hospital ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... hERG liability could substantially improve drug safety and minimize the cost of development. ... validating ion channel inhibition using cell lines and for cardiac toxicity using induced ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 NeuroVive Pharmaceutical ... today announced positive preclinical results demonstrating anti-fibrotic ... for non-alcoholic steatohepatitis (NASH), in an additional ... NV556 has previously shown similar anti-fibrotic ... Today, NeuroVive,s scientists present novel data demonstrating ...
(Date:4/19/2017)... 19, 2017  IRIDEX Corporation (Nasdaq: IRIX ... for the first quarter 2017 after the close of ... team will host a corresponding conference call beginning at ... Investors interested in listening to the conference call may ... or (703) 326-3030 for international callers, using conference ID: ...
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
Breaking Medicine Technology: